Clinical trials: Plasma Cell Tumor
Multiple Myeloma
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.
- Trial name
- NCT05478343
- Testing
- IM21 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Infection, Multiple Myeloma
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy.
- Trial name
- NCT00002850
- Testing
- ciprofloxacin, ofloxacin, 160 mg trimethoprim and 800 mg sulfamethoxazole
- Where
- 45 sites in United States, Peru and 1 more
- Volunteers
- 212 people
- Sponsor
- Gary Morrow
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma
Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)
This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.
- Trial name
- wCCyd (NCT01857115)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- Italy
- Volunteers
- 63 people
- Sponsor
- European Myeloma Network B.V.
Refractory Multiple Myeloma, Multiple Myeloma in Relapse
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT03702725
- Testing
- Ibrutinib, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Alliance Foundation Trials, LLC.
Multiple Myeloma
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
This study is intended to investigate the combination of the combination of dexamethasone (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) [ClaPd] in multiple myeloma patients who have relapsed or refractory…
- Trial name
- NCT01159574
- Testing
- dexamethasone, clarithromycin, Pomalidomide
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression
- Trial name
- EPC-MM+L (NCT06485076)
- Testing
- Early Palliative Care
- Where
- Canada
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Relapsed or Plateau-Phase Multiple Myeloma
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.
- Trial name
- NCT00259740
- Testing
- DENOSUMAB
- Volunteers
- 96 people
- Sponsor
- Amgen
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004088
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Examination of Trends in Multiple Myeloma Trial Patient Experiences
Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is…
- Trial name
- NCT05860179
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Multiple Myeloma
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
Multiple myeloma is difficult to treat with only anti-cancer medicine (called chemotherapy) or radiation alone. Sometimes higher doses of chemotherapy are used but when used can also lower blood counts.
- Trial name
- NCT01416246
- Testing
- Fractionated Stem Cell Infusions
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
- Trial name
- NCT04223661
- Testing
- Lenalidomide Pill, Dexamethasone, Daratumumab
- Where
- United States
- Sponsor
- Attaya Suvannasankha
Multiple Myeloma
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Study phase: phase III Study objective: Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT) Comparison of Bortezomib, Lenalidomide…
- Trial name
- HO95 (NCT01208766)
- Testing
- Bortezomib, Melphalan, Prednisone (VMP), 1 or 2 cycle(s) HDM (High Dose Melphalan), 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
- Where
- 208 sites in Australia, Austria and 14 more
- Volunteers
- 1,503 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Waldenstrom Macroglobulinemia
Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia
This is a French multicenter open label non-randomized Phase II trial evaluating the efficacy and tolerance of a combination of oral zanubrutinib and BGB-11417 in subjects aged 18 years and older with previously treated…
- Trial name
- WAZABI (NCT06547866)
- Testing
- zanubrutinib + BGB-11417
- Where
- 37 sites in France
- Volunteers
- 102 people
- Sponsor
- French Innovative Leukemia Organisation
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
Multiple Myeloma
PDD vs PAD to Treat Initially Diagnosed MM
The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.
- Trial name
- NCT02577783
- Testing
- PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone, PAD regimen: bortizomib, dexamethasone and doxorubicin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma
Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics
- Trial name
- NCT02182141
- Testing
- BIBF 1120 ES
- Volunteers
- 17 people
- Sponsor
- Boehringer Ingelheim
Plasma Cell Neoplasm
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders.
- Trial name
- NCT04080531
- Testing
- Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- Emory University
Multiple Myeloma
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
This is a multicenter, randomized, open label study designed to compare the efficacy and safety of lenalidomide with low-dose alkylating agents versus high-dose melphalan followed by stem cell support in newly diagnosed…
- Trial name
- NCT01091831
- Testing
- Cyclophosphamide, Lenalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 389 people
- Sponsor
- Fondazione EMN Italy Onlus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.